Special Authority (SA) and dispensing data for pembrolizumab, atezolizumab and durvalumab

Thank you for your request dated 20 July 2023 under the Official Information Act 1982 (OIA) for information relating to pembrolizumab, atezolizumab and durvalumab. You requested:

• The latest data by month on number of Special Authority’s – initial and renewal for monotherapy of KEYTRUDA (pembrolizumab) funded for NSCLC in New Zealand.
• The latest data by month on number of Special Authority’s – initial and renewal for KEYTRUDA (pembrolizumab) used in combination with chemotherapy funded for NSCLC in New Zealand.
• The latest data by month on number of Special Authority’s – initial and renewal for monotherapy of TECENTRIQ (atezolizumab) funded for NSCLC in New Zealand, (as previously received in the attached)
• The latest data by month on number of Special Authority’s – initial and renewal for monotherapy of IMFINZI (durvalumab) funded for NSCLC in New Zealand, (as previously received in the attached)
• The number of milligrams dispensed each day for each person who received pembrolizumab and atezolizumab for NSCLC up to your latest data set (including month dispensed as previously received in the attached)
• The total number of units in each dispensing of pembrolizumab and atezolizumab up to your latest data set (including month dispensed as previously received in the attached)

Please note, the OIA you referred to in your request was later identified to contain an issue, which has been rectified in the attached data. Please ignore the OIA dataset that was found online, which has since been taken down.

We have redacted a small amount of information from the documents as we consider this necessary to protect the privacy of natural persons (section 9(2)(a) of the OIA), these counts are shown as “<6”.

We trust that this information answers your queries. Please note, you have the right to make a complaint to the Ombudsman about our response to your OIA, under section 28(3) of the OIA. Details of how to make a complaint(external link) are on the Ombudsman’s website.

To make information more freely available, we publish selected OIA responses (excluding personal details) on our website. Please get in touch with us if you have any questions about this.